EPID-12. SURVIVAL IS ASSOCIATED WITH CIRCULATING B-CELLS AND AGE AMONG OLIGODENDROGLIOMA PATIENTS

Abstract

Abstract BACKGROUND Though patients with oligodendroglioma have improved outcomes versus astrocytomas, there remains marked variability in their survival experience that is unexplained by known prognostic factors. Immunomethylomics uses DNA methylation as a substitute for flow cytometry to characterize immune cells in whole blood. METHODS We applied immunomethylomics to archived blood samples from patients enrolled in the UCSF Adult Glioma Study including oligodendrogliomas (141); other adult diffuse glioma subtypes (347); and controls (454). RESULTS Median age of oligodendrogliomas was 44 years (range 19 – 83), 57% male, 75% white, and 60% received chemotherapy prior to blood draw. Oligodendroglioma patients had lower percent of B cell fractions (total, memory, naïve) than people without glioma. They also had higher percent of B cell (total, memory) and lymphocyte fractions (total, CD4-total and memory), basophil, eosinophil, and NK cells versus other glioma subtypes. Median overall survival in oligodendrogliomas was 17.5 years (95% CI 16.9 - NA) with median follow-up of 12 years (95% CI 11 – 14). Recursive partitioning analysis delineated two survival groups for oligodendroglioma patients based on age and percent B naïve cells. Best outcome, with median survival of 24.2 years (95% CI 20.4 – NR), was seen in patients < /= 42 years of age with a higher percent of B naïve cells ( >1.91%) (N = 37). Worst outcome, with median survival of 16.9 years (14.8 – NR), was seen in patients < /= 42 years of age with a lower percent of B naïve cells (< /= 1.91%) (N = 28) OR patients > 42 years of age (N = 76) (p = 0.00032). CONCLUSIONS An interaction between age and B naïve cell percentages may predict survival for oligodendroglioma patients. Immunomethylomics is a powerful tool for assessing immune status and these findings suggest that blood-immune profiles may be prognostic glioma patients.